Author

Jesús García-Donás

HM HospitalesORCID 0000-0001-7731-3601Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alberto CascóniD· 1 shared Alberto MartíniD· 1 shared Alejandra Ramos· 1 shared Alicia ArenasiD· 1 shared Ana Montero‐CalleiD· 1 shared Borja Vilaplana‐MartíiD· 1 shared Carlos ValdiviaiD· 1 shared Carolina EpifanoiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto CascónORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJan 24, 2025

Identification of a novel papillary renal cell carcinoma molecular subtype characterized by HIF-pathway over-activation

Javier de Nicolás‐Hernández, Alicia Arenas, Carlos Valdivia…·Cristina Rodríguez‐Antona

This paper identifies a novel molecular subtype of papillary renal cell carcinoma (pRCC) characterized by HIF-pathway overactivation, associated with poor prognosis and distinct biological features.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyMolecular OncologyPeer-reviewedJan 8, 2025

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds

Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández…·Ignacío Pérez de Castro

This study uses CRISPR to eliminate the FOXL2 c.402C>G mutation in granulosa tumor cells, reducing malignancy and identifying anti-tumoral compounds.

2 citations

humanproteomics

𝕏 PostBluesky